Faculty Profiles - SAKAMOTO Shinji

Papers - SAKAMOTO Shinji

Division display 21 - 40 of about 47 ／ All the affair displays >>

Mechanisms Underlying the Comorbidity of Schizophrenia and Type 2 Diabetes Mellitus. Reviewed International journal

Yutaka Mizuki, Shinji Sakamoto, Yuko Okahisa, Yuji Yada, Nozomu Hashimoto, Manabu Takaki, Norihito Yamada

The international journal of neuropsychopharmacology 24 ( 5 ) 367 - 382 2021.5

Language：English Publishing type：Research paper (scientific journal)

The mortality rate of patients with schizophrenia is high, and life expectancy is shorter by 10 to 20 years. Metabolic abnormalities including type 2 diabetes mellitus (T2DM) are among the main reasons. The prevalence of T2DM in patients with schizophrenia may be epidemiologically frequent because antipsychotics induce weight gain as a side effect and the cognitive dysfunction of patients with schizophrenia relates to a disordered lifestyle, poor diet, and low socioeconomic status. Apart from these common risk factors and risk factors unique to schizophrenia, accumulating evidence suggests the existence of common susceptibility genes between schizophrenia and T2DM. Functional proteins translated from common genetic susceptibility genes are known to regulate neuronal development in the brain and insulin in the pancreas through several common cascades. In this review, we discuss common susceptibility genes, functional cascades, and the relationship between schizophrenia and T2DM. Many genetic and epidemiological studies have reliably associated the comorbidity of schizophrenia and T2DM, and it is probably safe to think that common cascades and mechanisms suspected from common genes' functions are related to the onset of both schizophrenia and T2DM. On the other hand, even when genetic analyses are performed on a relatively large number of comorbid patients, the results are sometimes inconsistent, and susceptibility genes may carry only a low or moderate risk. We anticipate future directions in this field.

DOI： 10.1093/ijnp/pyaa097

PubMed

researchmap

Rituximab Was Effective for Treatment of Anti–N-Methyl-d-Aspartate Receptor Encephalitis in Early Adolescence in Initially Suspected Dissociative Disorder Reviewed

Takashi Shibata, Hiroki Kawai, Shinji Sakamoto, Ko Tsutsui, Takashi Kanbayashi, Keiko Tanaka, Manabu Takaki

Clinical Neuropharmacology 44 ( 3 ) 99 - 100 2021.5

The relationship between plasma clozapine concentration and clinical outcome: a cross-sectional study Reviewed International journal

Yuji Yada, Kohei Kitagawa, Shinji Sakamoto, Atsushi Ozawa, Akihiro Nakada, Hiroko Kashiwagi, Yuko Okahisa, Soshi Takao, Manabu Takaki, Yoshiki Kishi, Norihito Yamada

ACTA PSYCHIATRICA SCANDINAVICA 143 ( 3 ) 227 - 237 2021.3

Language：English Publishing type：Research paper (scientific journal) Publisher：WILEY

Objective There is no report that statistically evaluates the therapeutic reference (350-600 ng/ml) and adverse drug reaction (ADR) range (>1000 ng/ml) of clozapine (CLZ) recommended by the Arbeitsgemeinschaft fur Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) consensus guidelines in an isolated and large sampling study.Methods We administered CLZ to 131 Japanese patients with treatment-resistant schizophrenia in a multicenter cross-sectional study. Plasma CLZ concentrations were assayed by high-performance liquid chromatography using trough sampling. The Brief Psychiatric Rating Scale (BPRS) and severe dose-dependent ADR (sedation, myoclonus, and seizures) were analyzed statistically after adjusting for possible confounders.Results The daily CLZ dosage showed a moderately positive relationship with the plasma concentration (r = 0.49, p 0.001). Every 100 ng/ml increase in plasma CLZ concentration improved the total BPRS score 1.95% (95% CI: 0.89-3.01, p 0.001) and the odds ratio (OR) 1.38 (95% CI: 1.14-1.66, p = 0.001) for BPRS response. Compared with concentrations below 350 ng/ml CLZ, 350-600 ng/ml (11.12%; 95% CI: 2.52-19.72, p = 0.012) and 600-1000 ng/ml (11.05%; 95% CI: 2.40-19.71, p = 0.013) showed significant improvement in the total BPRS score. Dosages above 1000 ng/ml showed greater improvement (25.36%; 95% CI: 13.08-37.64, p 0.001) of the total BPRS score but more severe ADRs than dosages below 1000 ng/ml (OR: 31.72; 95% CI: 1.04-968.81, p = 0.048).Conclusion The AGNP therapeutic reference range (350-600 ng/ml) is useful, and a dose above 1000 ng/ml is potentially more effective but carries the risk of severe ADRs in the central nervous system.

DOI： 10.1111/acps.13264

Web of Science

PubMed

researchmap

Electroconvulsive Therapy Is Effective and Safe for Serious Catatonia-Related Ileus: Two Case Reports Reviewed

Yuto Yamada, Masaki Fujiwara, Ryuhei So, Satoru Edahiro, Yukiko Matsui, Shinji Sakamoto, Kiyohiro Kawada, Manabu Takaki, Suguru Ishizu, Keiko Kanazawa, Yoshiki Kishi, Norihito Yamada

The journal of ECT 2020.12

Electroconvulsive Therapy Is Effective and Safe for Serious Catatonia-Related Ileus Two Case Reports Reviewed International journal

Yuto Yamada, Masaki Fujiwara, Ryuhei So, Satoru Edahiro, Yukiko Matsui, Shinji Sakamoto, Kiyohiro Kawada, Manabu Takaki, Suguru Ishizu, Keiko Kanazawa, Yoshiki Kishi, Norihito Yamada

JOURNAL OF ECT 36 ( 4 ) E49 - E51 2020.12

Switching strategies for antipsychotic monotherapy in schizophrenia: a multi-center cohort study of aripiprazole Reviewed

Yoshiaki Obayashi, Satoshi Mitsui, Shinji Sakamoto, Nozomu Minao, Bunta Yoshimura, Toshiki Kono, Yuji Yada, Yuko Okahisa, Soshi Takao, Yoshiki Kishi, Toshihiko Takeda, Manabu Takaki, Norihito Yamada

Psychopharmacology 237 ( 1 ) 167 - 175 2020.1

Language：English Publishing type：Research paper (scientific journal)

Rationale: Changing antipsychotics of patients with chronic schizophrenia involves several risks. Switching to aripiprazole is especially difficult. We investigated switching methods and related factors for successful switching patients with chronic schizophrenia to aripiprazole. Objectives: This study was a multi-center historical cohort study and approved by the research ethics committee of Okayama University Hospital and Okayama Psychiatric Medical Center. We compared survival proportions of 178 chronic schizophrenia patients who continued aripiprazole monotherapy for 6 months after non-direct switching (add-on switching (n = 45), cross switching (n = 62)) or direct switching (n = 71). We adjusted possible confounders using a Cox proportional hazards model. Results: Of patients with chronic schizophrenia, 56.7% (101/178) were switched to aripiprazole monotherapy, and 55.0% (98/178) showed improvement in symptoms as demonstrated by the Clinical Global Impression Severity score. Kaplan-Meier survival curves showed that non-direct switching had a higher survival proportion than direct switching (log-rank test, p = 0.012). Even after adjusting for several variables using a Cox proportional hazards model, add-on switching had a significantly lower hazard at 6 months than direct switching (hazard ratio 0.42, 95% confidence interval 0.21–0.82, P = 0.01). In cases of switching to aripiprazole for psychiatric symptoms, non-direct switching had a lower hazard than direct switching (hazard ratio 0.41, 95% confidence interval 0.21–0.81, P = 0.01) but was not significant for adverse reaction. When aripiprazole was switched from olanzapine, add-on switch showed the lowest hazard ratio for continuation (hazard ratio 0.29, 95% confidence interval 0.07–1.11, P = 0.07). Conclusions: Flexibility in strategies when switching to aripiprazole may induce a better outcome for patients with chronic schizophrenia.

DOI： 10.1007/s00213-019-05352-7

Scopus

PubMed

researchmap

Anti-NMDA-receptor antibody in initial diagnosis of mood disorder Reviewed

Hiroki Kawai, Manabu Takaki, Shinji Sakamoto, Takashi Shibata, Ayaka Tsuchida, Bunta Yoshimura, Yuji Yada, Namiko Matsumoto, Kota Sato, Koji Abe, Yuko Okahisa, Yoshiki Kishi, Soshi Takao, Ko Tsutsui, Takashi Kanbayashi, Keiko Tanaka, Norihito Yamada

European Neuropsychopharmacology 29 ( 9 ) 1041 - 1050 2019.9

Anti-N-Methyl-D-Aspartate Receptor Encephalitis in Psychiatry. Reviewed

Shinji Sakamoto, Hiroki Kawai, Yuko Okahisa, Ko Tsutsui, Takashi Kanbayashi, Keiko Tanaka, Yutaka Mizuki, Manabu Takaki, Norihito Yamada

Acta medica Okayama 73 ( 3 ) 189 - 195 2019.6

Authorship：Lead author,　Corresponding author Language：English Publishing type：Research paper (scientific journal)

Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a recently-discovered autoimmune disorder in which antibodies target NMDAR in the brain. The number of reported cases of anti-NMDAR encephalitis has increased rapidly. Anti-NMDAR encephalitis can be mistakenly diagnosed as psychiatric disorders because many patients present with prominent psychiatric symptoms and visit psychiatric institutions first. Thus, psychiatrists should cultivate a better understanding of anti-NMDAR encephalitis. In this review, we present the mechanisms, epidemiology, symptoms and clinical course, diagnostic tests, treatment and outcomes of patients with anti-NMDAR encephalitis. Furthermore, we discuss the diversity of clinical spectra of anti-NMDAR encephalitis, and demonstrate a differential diagnosis of psychiatric disease from the perspective of psychiatry.

DOI： 10.18926/AMO/56860

PubMed

researchmap

Predictors of remission during acute treatment of first-episode schizophrenia patients involuntarily hospitalized and treated with algorithm-based pharmacotherapy: secondary analysis of an observational study. Reviewed

Yoshimura B, Sakamoto S, Sato K, Takaki M, Yamada N

Early Interv Psychiatry 13 ( 3 ) 589 - 597 2019.5

Incidence and predictors of acute akathisia in severely ill patients with first-episode schizophrenia treated with aripiprazole or risperidone: secondary analysis of an observational study. Reviewed International journal

Bunta Yoshimura, Kojiro Sato, Shinji Sakamoto, Masaru Tsukahara, Yusaku Yoshimura, Ryuhei So

Psychopharmacology 236 ( 2 ) 723 - 730 2019.2

Language：English Publishing type：Research paper (scientific journal)

RATIONALE: In the antipsychotic treatment of schizophrenia with little medication history, especially in drug-naïve cases, predictors of side effects are important. However, predictors of antipsychotic-induced akathisia remain unclear. OBJECTIVES: This study aimed to investigate the incidence and predictors of acute akathisia in severely ill patients with first-episode schizophrenia spectrum disorders (FES). METHODS: This is a secondary analysis of our retrospective observational study. Data were obtained from 129 consecutive patients with FES involuntarily hospitalized in a tertiary psychiatric public hospital and treated with aripiprazole or risperidone. The primary outcome was the presence of acute akathisia during the first 1 month. A Cox proportional hazard model was used to examine significant predictors of the onset of akathisia. RESULTS: Acute akathisia was diagnosed in 54 patients (42%). Neither antipsychotics (aripiprazole or risperidone), duration of untreated psychosis, iron deficiency, sex, age nor baseline symptomatic severity was identified as an independent predictor of akathisia. Rapid risperidone initiation significantly increased the onset of akathisia (adjusted hazard ratio [HR], 6.47; 95%; 95% confidence interval [CI], 1.94-21.65; p = 0.002), but rapid aripiprazole initiation did not (adjusted HR, 1.08; 95% CI, 0.50-2.31; p = 0.84). A significant interaction was found between rapid antipsychotic initiation and the risk of akathisia with aripiprazole versus risperidone (p = 0.027). CONCLUSIONS: Severely ill patients with FES initiating aripiprazole or risperidone could have a high risk for akathisia. Rapid risperidone initiation should be avoided because of the risk for akathisia, and careful monitoring of akathisia may be necessary for all patients initiating aripiprazole.

DOI： 10.1007/s00213-018-5101-7

PubMed

researchmap

Incidence and predictors of acute akathisia in severely ill patients with first-episode schizophrenia treated with aripiprazole or risperidone-secondary analysis of an observational study-. Reviewed

Yoshimura B, Sato K, Sakamoto S, Tsukahara M, Yoshimura Y, So R

Psychopharmacology (Berl) 236 ( 2 ) 723 - 730 2018.11

Effects of the antipsychotics haloperidol, clozapine, and aripiprazole on the dendritic spine. Reviewed

Takaki M, Kodama M, Mizuki Y, Kawai H, Yoshimura B, Kishimoto M, Sakamoto S, Okahisa Y, Yamada N

European Neuropsychopharmacology 28 ( 5 ) 610 - 619 2018.5

Restless Genital Syndrome Induced by Milnacipran. Reviewed

Miyake K, Takaki M, Sakamoto S, Kawada K, Inoue S, Yamada N

Clinical neuropharmacology 41 ( 3 ) 109 - 110 2018.5

Rare loss of function mutations in N-methyl-D-aspartate glutamate receptors and their contributions to schizophrenia susceptibility Reviewed

Yanjie Yu, Yingni Lin, Yuto Takasaki, Chenyao Wang, Hiroki Kimura, Jingrui Xing, Kanako Ishizuka, Miho Toyama, Itaru Kushima, Daisuke Mori, Yuko Arioka, Yota Uno, Tomoko Shiino, Yukako Nakamura, Takashi Okada, Mako Morikawa, Masashi Ikeda, Nakao Iwata, Yuko Okahisa, Manabu Takaki, Shinji Sakamoto, Toshiyuki Someya, Jun Egawa, Masahide Usami, Masaki Kodaira, Akira Yoshimi, Tomoko Oya-Ito, Branko Aleksic, Kinji Ohno, Norio Ozaki

TRANSLATIONAL PSYCHIATRY 8 ( 1 ) 2018.1

Language：English Publishing type：Research paper (scientific journal) Publisher：NATURE PUBLISHING GROUP

In schizophrenia (SCZ) and autism spectrum disorder (ASD), the dysregulation of glutamate transmission through N-methyl-D-aspartate receptors (NMDARs) has been implicated as a potential etiological mechanism. Previous studies have accumulated evidence supporting NMDAR-encoding genes' role in etiology of SCZ and ASD. We performed a screening study for exonic regions of GRIN1, GRIN2A, GRIN2C, GRIN2D, GRIN3A, and GRIN3B, which encode NMDAR subunits, in 562 participates (370 SCZ and 192 ASD). Forty rare variants were identified including 38 missense, 1 frameshift mutation in GRIN2C and 1 splice site mutation in GRIN2D. We conducted in silico analysis for all variants and detected seven missense variants with deleterious prediction. De novo analysis was conducted if pedigree samples were available. The splice site mutation in GRIN2D is predicted to result in intron retention by minigene assay. Furthermore, the frameshift mutation in GRIN2C and splice site mutation in GRIN2D were genotyped in an independent sample set comprising 1877 SCZ cases, 382 ASD cases, and 2040 controls. Both of them were revealed to be singleton. Our study gives evidence in support of the view that ultra-rare variants with loss of function (frameshift, nonsense or splice site) in NMDARs genes may contribute to possible risk of SCZ.

DOI： 10.1038/s41398-017-0061-y

Web of Science

researchmap

Human Rho Guanine Nucleotide Exchange Factor 11 (ARHGEF11) Regulates Dendritic Morphogenesis. Reviewed

Mizuki Y, Takaki M, Sakamoto S, Okamoto S, Kishimoto M, Okahisa Y, Itoh M, Yamada N

Int J Mol Sci 18 ( 1 ) E67 - E67 2016.12

Expression Profiles and Neurocognitive/Social Functions as a Predictive Biomarker of Schizophrenia Reviewed

Yuko Okahisa, Shinji Sakamoto, Makiko Kishimoto, Manabu Takaki, Norihito Yamada

EARLY INTERVENTION IN PSYCHIATRY 10 153 - 153 2016.10

Individual risk alleles of susceptibility to schizophrenia are associated with poor clinical and social outcomes Reviewed

Journal of human genetics 61 ( 4 ) 329 - 334 2016.4

Anti-Inflammatory Therapy and Immunotherapy Were Partially Effective in a Patient With Anti-N-Methyl-D-Aspartate Receptor Antibodies and a Special Subgroup of Treatment-Resistant Schizophrenia. Reviewed

Senda M, Bessho K, Oshima E, Sakamoto S, Tanaka K, Tsutsui K, Kanbayashi T, Takaki M, Yoshimura B

J Clin Psychopharmacol 36 ( 1 ) 92 - 93 2016.2

Mayuko Senda, Kazunori Bessho, Etsuko Oshima, Shinji Sakamoto, Keiko Tanaka, Ko Tsutsui, Takashi Kanbayashi, Manabu Takaki, Bunta Yoshimura

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY 36 ( 1 ) 92 - 93 2016.2

Human Rho guanine nucleotide exchange factor 11 gene is associated with schizophrenia in a Japanese population Reviewed

Mizuki Yutaka, Takaki Manabu, Okahisa Yuko, Sakamoto Shinji, Kodama Masafumi, Ujike Hiroshi, Uchitomi Yosuke

Human Psychopharmacology: Clinical and Experimental 29 ( 6 ) 552 - 558 2014.11

　 PREV - NEXT 　

< SAKAMOTO Shinji >

Papers - SAKAMOTO Shinji